Form 4: Recursion Pharmaceuticals Director Blake Borgeson Sells Shares Under 10b5-1 Plan

Director Blake Borgeson of Recursion Pharmaceuticals sold 11,447 shares of Class A Common Stock at an average price of $7.9465 on April 30, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 30, 2024, Blake Borgeson, a director of Recursion Pharmaceuticals, sold 11,447 shares of Class A Common Stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on August 18, 2023.
• The shares were sold at a weighted average price of $7.9465, with individual trades ranging from $7.81 to $8.26.
• Following the transaction, Borgeson directly owns 7,218,414 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. The sale was conducted under a pre-arranged trading plan, suggesting it's not necessarily indicative of a negative outlook on the company.

Industry Context

Sales by insiders are a common occurrence and are often related to personal financial planning rather than a reflection of the company's prospects. Rule 10b5-1 plans are designed to allow insiders to sell shares without being accused of trading on non-public information.

Stakeholder Impact

• The sale of shares by a director could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates